Submitted:
24 October 2023
Posted:
25 October 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Methods
2.1. Study Design, Sources, and Population
2.2. Detection of Circulating Biomarkers
2.3. Statistical Analysis
3. Results
3.1. Baseline Characteristics
3.2. Association of eGFR with the Inflammatory and Damage Circulating Biomarkers
3.3. eGFR-Based CKD Risk Definition
3.4. mGPS Categories and Risk for CKD in Different Age-Classes
4. Discussion
5. Strengths and limitations
6. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflict of Interest Disclosures
References
- van der Burgh AC, Rizopoulos D, Ikram MA, Hoorn EJ, Chaker L. Determinants of the Evolution of Kidney Function With Age. Kidney Int Rep. 2021;6(12):3054-3063. [CrossRef]
- Dybiec J, Szlagor M, Młynarska E, Rysz J, Franczyk B. Structural and Functional Changes in Aging Kidneys. Int J Mol Sci. 2022;23(23):15435. [CrossRef]
- Balistreri CR. Anti-Inflamm-Ageing and/or Anti-Age-Related Disease Emerging Treatments: A Historical Alchemy or Revolutionary Effective Procedures? Mediators Inflamm. 2018; 2018:3705389. [CrossRef]
- Levey AS, Coresh J, Tighiouart H, Greene T, Inker LA. Measured and estimated glomerular filtration rate: Current status and future directions. Nat Rev Nephrol. 2020;16(1):51-64. [CrossRef]
- Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, Badve SV, Caravaca-Fontán F, Del Vecchio L, Floege J, Goicoechea M, Haaland B, Herrington WG, Imai E, Jafar TH, Lewis JB, Li PKT, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Wetzels JFM, Woodward M, Heerspink HJL; CKD-EPI Clinical Trials Consortium. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023. [CrossRef]
- Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutiérrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS; Chronic Kidney Disease Epidemiology Collaboration. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-1749. [CrossRef]
- Levey AS, Grams ME, Inker LA. Use of eGFR in Older Adults with Kidney Disease. Reply. N Engl J Med. 2022;387(6):575. [CrossRef]
- Carnevale V, Tinti MG. Use of eGFR in Older Adults with Kidney Disease. N Engl J Med. 2022;387(6):574-575. [CrossRef]
- Toyama T, Kitagawa K, Oshima M, Kitajima S, Hara A, Iwata Y, Sakai N, Shimizu M, Hashiba A, Furuichi K, Wada T. Age differences in the relationships between risk factors and loss of kidney function: A general population cohort study. BMC Nephrol. 2020;21(1):477. [CrossRef]
- Minutolo R, Gabbai FB, Chiodini P, Provenzano M, Borrelli S, Garofalo C, Bellizzi V, Russo D, Conte G, De Nicola L; Collaborative Study Group on the Conservative Treatment of CKD of the Italian Society of Nephrology. Sex Differences in the Progression of CKD Among Older Patients: Pooled Analysis of 4 Cohort Studies. Am J Kidney Dis. 2020;75(1):30-38. [CrossRef]
- Ravani P, Quinn R, Fiocco M, Liu P, Al-Wahsh H, Lam N, Hemmelgarn BR, Manns BJ, James MT, Joanette Y, Tonelli M. Association of Age With Risk of Kidney Failure in Adults With Stage IV Chronic Kidney Disease in Canada. JAMA Netw Open. 2020;3(9):e2017150. [CrossRef]
- Liu P, Quinn RR, Lam NN, Elliott MJ, Xu Y, James MT, Manns B, Ravani P. Accounting for Age in the Definition of Chronic Kidney Disease. JAMA Intern Med. 2021;181(10):1359-1366. [CrossRef]
- Noronha IL, Santa-Catharina GP, Andrade L, Coelho VA, Jacob-Filho W, Elias RM. Glomerular filtration in the aging population. Front Med (Lausanne). 2022;9:769329. [CrossRef]
- Jaques DA, Vollenweider P, Bochud M, Ponte B. Aging and hypertension in kidney function decline: A 10 year population-based study. Front Cardiovasc Med. 2022;9:1035313. [CrossRef]
- Singh-Manoux A, Oumarou-Ibrahim A, Machado-Fragua MD, Dumurgier J, Brunner EJ, Kivimaki M, Fayosse A, Sabia S. Association between kidney function and incidence of dementia: 10-year follow-up of the Whitehall II cohort study. Age Ageing. 2022;51(1):afab259. [CrossRef]
- Baylis C. Sexual dimorphism in the aging kidney: Differences in the nitric oxide system. Nat Rev Nephrol. 2009;5(7):384-96. [CrossRef]
- Delanaye P, Jager KJ, Bökenkamp A; et al. CKD: A call for an age-adapted definition. J AmSoc Nephrol. 2019;30(10):1785-1805. [CrossRef]
- Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122(7):474-488. [CrossRef]
- Stefan G, Stancu S, Zugravu A, Capusa C. Inflammation-based modified Glasgow prognostic score and renal outcome in chronic kidney disease patients: Is there a relationship? Intern Med J. 2022;52(6):968-974. [CrossRef]
- Wu TH, Tsai YT, Chen KY, Yap WK, Luan CW. Utility of High-Sensitivity Modified Glasgow Prognostic Score in Cancer Prognosis: A Systemic Review and Meta-Analysis. Int J Mol Sci. 2023;24(2):1318. Published 2023 Jan 10. [CrossRef]
- Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From discoveries in ageing research to therapeutics for healthy ageing. Nature. 2019;571(7764):183-192. [CrossRef]
- Yoshitomi R, Nakayama M, Sakoh T, Fukui A, Katafuchi E, Seki M, Tsuda S, Nakano T, Tsuruya K, Kitazono T. High neutrophil/lymphocyte ratio is associated with poor renal outcomes in Japanese patients with chronic kidney disease. Ren Fail. 2019;41(1):238-243. [CrossRef]
- Mureșan, A.V.; Russu, E.; Arbănași, E.M.; Kaller, R.; Hosu, I.; Arbănași, E.M.; Voidăzan, S.T. The Predictive Value of NLR, MLR, and PLR in the Outcome of End-Stage Kidney Disease Patients. Biomedicines 2022, 10, 1272. [CrossRef]
- Bowe B, Xie Y, Li T, Mokdad AH, Xian H, Yan Y, Maddukuri G, Al-Aly Z. Changes in the US Burden of Chronic Kidney Disease From 2002 to 2016: An Analysis of the Global Burden of Disease Study. JAMA Netw Open. 2018 Nov 2;1(7):e184412. [CrossRef]
- Ke C, Liang J, Liu M, Liu S, Wang C. Burden of chronic kidney disease and its risk-attributable burden in 137 low-and middle-income countries, 1990-2019: Results from the global burden of disease study 2019. BMC Nephrol. 2022 Jan 5;23(1):17. [CrossRef]
- Conte C, Antonelli G, Melica ME, Tarocchi M, Romagnani P, Peired AJ. Role of Sex Hormones in Prevalent Kidney Diseases. Int J Mol Sci. 2023 May 4;24(9):8244. [CrossRef]
- Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, Nee R. Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy. Am J Nephrol. 2021;52(2):98-107. [CrossRef]
- Yoo JH, Kim G, Park SW; et al. Effects of low skeletal muscle mass and sarcopenic obesity on albuminuria: A 7-year longitudinal study. Sci Rep. 2020;10:5774. [CrossRef]
- Balistreri CR. Promising Strategies for Preserving Adult Endothelium Health and Reversing Its Dysfunction: From Liquid Biopsy to New Omics Technologies and Noninvasive Circulating Biomarkers. Int J Mol Sci. 2022 Jul 7;23(14):7548. [CrossRef]
- Delanaye P, Jager KJ, Bökenkamp A, Christensson A, Dubourg L, Eriksen BO, Gaillard F, Gambaro G, van der Giet M, Glassock RJ, Indridason OS, van Londen M, Mariat C, Melsom T, Moranne O, Nordin G, Palsson R, Pottel H, Rule AD, Schaeffner E, Taal MW, White C, Grubb A, van den Brand JAJG. CKD: A Call for an Age-Adapted Definition. J Am Soc Nephrol. 2019 Oct;30(10):1785-1805. [CrossRef]
- Mihai S, Codrici E, Popescu ID, Enciu AM, Albulescu L, Necula LG; et al. Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome. J Immunol Res. 2018;2018:2180373. [CrossRef]
- Ix JH, Shlipak MG. The Promise of Tubule Biomarkers in Kidney Disease: A Review. Am J Kidney Dis. 2021;78(5):719-727. [CrossRef]



| Characteristics | Overall | Age Classes | |||||||
| (18-40) | (40-60) | (60-80) | (80-100) | ||||||
| F | M | F | M | F | M | F | M | ||
| N=57449 | N=9152 | N=5637 | N=8003 | N=8592 | N=8864 | N=10883 | N=3310 | N=3008 | |
| eGFRClass: | |||||||||
| G1 | 32597 (57.7%) | 8800 (97.4%) | 4640 (83.5%) | 6325 (80.1%) | 4775 (56.4%) | 4026 (46.4%) | 3193 (29.8%) | 477 (14.8%) | 361 (12.2%) |
| G2 | 13369 (23.7%) | 190 (2.10%) | 749 (13.5%) | 1189 (15.1%) | 2627 (31.1%) | 2995 (34.5%) | 3810 (35.6%) | 1081 (33.5%) | 728 (24.7%) |
| G3a | 4255 (7.53%) | 18 (0.20%) | 72 (1.30%) | 156 (1.98%) | 496 (5.86%) | 754 (8.69%) | 1542 (14.4%) | 668 (20.7%) | 549 (18.6%) |
| G3b | 2839 (5.02%) | 11 (0.12%) | 24 (0.43%) | 81 (1.03%) | 238 (2.81%) | 429 (4.94%) | 998 (9.32%) | 532 (16.5%) | 526 (17.8%) |
| G4 | 1785 (3.16%) | 8 (0.09%) | 21 (0.38%) | 62 (0.79%) | 126 (1.49%) | 234 (2.70%) | 573 (5.35%) | 325 (10.1%) | 436 (14.8%) |
| G5 | 1664 (2.94%) | 12 (0.13%) | 51 (0.92%) | 84 (1.06%) | 198 (2.34%) | 240 (2.77%) | 588 (5.49%) | 142 (4.40%) | 349 (11.8%) |
| mGPS: | |||||||||
| mGPS0a | 2681 (47.2%) | 435 (69.7%) | 328 (63.0%) | 371 (58.3%) | 420 (52.7%) | 421 (45.0%) | 419 (36.6%) | 167 (29.1%) | 120 (27.1%) |
| mGPS0b | 179 (3.15%) | 9 (1.44%) | 9 (1.73%) | 11 (1.73%) | 22 (2.76%) | 37 (3.96%) | 45 (3.93%) | 29 (5.06%) | 17 (3.84%) |
| mGPS1 | 1743 (30.7%) | 161 (25.8%) | 159 (30.5%) | 180 (28.3%) | 254 (31.9%) | 269 (28.8%) | 411 (35.9%) | 162 (28.3%) | 147 (33.2%) |
| mGPS2 | 1072 (18.9%) | 19 (3.04%) | 25 (4.80%) | 74 (11.6%) | 101 (12.7%) | 208 (22.2%) | 271 (23.6%) | 215 (37.5%) | 159 (35.9%) |
| CRE (mg/dl) | 1.05 (1.03) | 0.65 (0.34) | 0.98 (0.79) | 0.82 (0.74) | 1.12 (1.15) | 1.03 (0.98) | 1.32 (1.28) | 1.32 (1.06) | 1.64 (1.46) |
| eGFR | 94.3 (41.9) | 129 (16.5) | 122 (58.0) | 103 (22.1) | 97.9 (42.5) | 80.9 (25.8) | 74.1 (39.0) | 58.4 (25.1) | 52.8 (34.2) |
| WBC (x103/µl) | 8.99 (5.24) | 9.41 (4.95) | 9.20 (5.37) | 8.26 (4.74) | 9.07 (6.14) | 8.63 (4.79) | 8.93 (4.55) | 9.83 (5.95) | 9.46 (6.55) |
| RDW % | 14.5 (2.11) | 14.2 (1.87) | 13.5 (1.43) | 14.5 (2.24) | 14.0 (1.77) | 14.7 (2.27) | 14.7 (2.12) | 15.5 (2.47) | 15.4 (2.35) |
| NL (x103/µL) | 6.21 (4.33) | 6.62 (4.65) | 6.07 (3.70) | 5.45 (3.65) | 6.09 (5.18) | 5.94 (3.95) | 6.23 (3.83) | 7.37 (4.80) | 6.90 (5.14) |
| LN (x103/µL) | 1.92 (2.16) | 1.99 (0.80) | 2.20 (3.48) | 2.02 (1.27) | 2.05 (1.39) | 1.88 (2.53) | 1.77 (1.94) | 1.60 (3.22) | 1.62 (3.28) |
| NL/LN | 4.72(6.83) | 4.15 (4.32) | 3.86 (4.91) | 3.54 (4.33) | 4.02 (5.12) | 4.67 (6.62) | 5.32 (8.00) | 7.93 (12.7) | 7.59 (9.96) |
| MN (x103/µL) | 0.67 (0.96) | 0.64 (0.28) | 0.72 (0.57) | 0.60 (1.75) | 0.71 (0.87) | 0.62 (0.53) | 0.72 (1.06) | 0.71 (0.75) | 0.76 (1.00) |
| ES (x103/µL) | 0.14 (0.19) | 0.11 (0.16) | 0.16 (0.18) | 0.13 (0.16) | 0.16 (0.23) | 0.13 (0.17) | 0.15 (0.23) | 0.10 (0.14) | 0.13 (0.18) |
| BS (x103/µL) | 0.05 (0.08) | 0.04 (0.07) | 0.05 (0.06) | 0.05 (0.13) | 0.05 (0.05) | 0.05 (0.06) | 0.05 (0.05) | 0.05 (0.08) | 0.04 (0.06) |
| MDW (SDV) | 19.2 (3.20) | 19.3 (2.66) | 18.4 (2.81) | 18.9 (2.79) | 18.6 (3.05) | 19.5 (3.35) | 19.1 (3.30) | 20.3 (3.88) | 20.3 (4.21) |
| CRP (mg/dL) | 2.57 (5.80) | 1.36 (3.73) | 1.38 (3.93) | 1.78 (4.92) | 1.96 (5.14) | 2.85 (6.13) | 3.46 (6.79) | 4.10 (6.93) | 4.34 (7.13) |
| PCT (µg/L) | 5.55 (19.3) | 1.19 (2.75) | 1.83 (8.69) | 6.51 (22.4) | 3.67 (14.8) | 5.30 (19.1) | 6.73 (22.6) | 5.93 (16.2) | 7.77 (23.7) |
| Albumin (g/dL) | 3.95 (0.60) | 3.95 (0.47) | 4.45 (0.57) | 4.10 (0.55) | 4.10 (0.64) | 3.88 (0.62) | 3.84 (0.64) | 3.54 (0.61) | 3.53 (0.60) |
| CPK (U/L) | 202 (942) | 118 (254) | 346 (1631) | 165 (1141) | 229 (1102) | 150 (492) | 205 (765) | 183 (684) | 194 (591) |
| ALP (U/L) | 26.4 (71.1) | 18.8 (45.4) | 32.5 (90.0) | 23.7 (57.2) | 33.8 (95.0) | 24.6 (54.0) | 27.7 (72.7) | 26.1 (74.2) | 28.5 (85.1) |
| Albumin/CRE | 1.03 (2.29) | 2.80 (3.50) | 0.73 (1.88) | 1.01 (2.34) | 0.61 (1.62) | 0.73 (1.86) | 0.55 (1.45) | 0.68 (1.55) | 0.51 (1.25) |
| eGFR Class (ref. category G1) | Fixed Factors | OR | 95% CI | p-value | |
|---|---|---|---|---|---|
| Lowe limit | Upper limit | ||||
| G2 | Age Class: | ||||
| (18-40) vs (80-100) | 0.03 | 0.03 | 0.03 | <0.001 | |
| (40-60) vs (80-100) | 0.14 | 0.12 | 0.15 | <0.001 | |
| (60-80) vs (80-100) | 0.39 | 0.35 | 0.42 | <0.001 | |
| Gender (F vs M) | 0.44 | 0.42 | 0.46 | <0.001 | |
| Age Class: | |||||
| G3a | (18-40) vs (80-100) | 0.00 | 0.00 | 0.01 | <0.001 |
| (40-60) vs (80-100) | 0.03 | 0.03 | 0.04 | <0.001 | |
| (60-80) vs (80-100) | 0.19 | 0.17 | 0.21 | <0.001 | |
| Gender (F vs M) | 0.34 | 0.32 | 0.37 | <0.001 | |
| G3b | Age Class: | ||||
| (18-40) vs (80-100) | 0.00 | 0.00 | 0.00 | <0.001 | |
| (40-60) vs (80-100) | 0.02 | 0.02 | 0.02 | <0.001 | |
| (60-80) vs (80-100) | 0.13 | 0.12 | 0.15 | <0.001 | |
| Gender (F vs M) | 0.32 | 0.29 | 0.35 | <0.001 | |
| G4 | Age Class: | ||||
| (18-40) vs (80-100) | 0.00 | 0.00 | 0.00 | <0.001 | |
| (40-60) vs (80-100) | 0.01 | 0.01 | 0.02 | <0.001 | |
| (60-80) vs (80-100) | 0.10 | 0.09 | 0.12 | <0.001 | |
| Gender (F vs M) | 0.28 | 0.25 | 0.31 | <0.001 | |
| G5 | Age Class: | ||||
| (18-40) vs (80-100) | 0.01 | 0.01 | 0.01 | <0.001 | |
| (40-60) vs (80-100) | 0.03 | 0.03 | 0.04 | <0.001 | |
| (60-80) vs (80-100) | 0.16 | 0.14 | 0.18 | <0.001 | |
| Gender (F vs M) | 0.23 | 0.20 | 0.25 | <0.001 | |
| mGPS (ref. mGPS2) | Fixed Factors | OR | 95% CI | p-value | |
|---|---|---|---|---|---|
| Lowe limit | Upper limit | ||||
| mGPS0a | Age Class: | ||||
| (18-40) vs (80-100) | 22.77 | 16.20 | 32.02 | <0.001 | |
| (40-60) vs (80-100) | 6.05 | 4.83 | 7.58 | <0.001 | |
| (60-80) vs (80-100) | 2.34 | 1.93 | 2.84 | <0.001 | |
| Gender (F vs M) | 1.22 | 1.05 | 1.42 | 0.009 | |
| Age Class: | |||||
| mGPS0b | (18-40) vs (80-100) | 3.33 | 1.78 | 6.24 | <0.001 |
| (40-60) vs (80-100) | 1.54 | 0.95 | 2.49 | 0.081 | |
| (60-80) vs (80-100) | 1.40 | 0.95 | 2.06 | 0.092 | |
| Gender (F vs M) | 1.02 | 0.74 | 1.41 | 0.889 | |
| mGPS1 | Age Class: | ||||
| (18-40) vs (80-100) | 8.76 | 6.18 | 12.43 | <0.001 | |
| (40-60) vs (80-100) | 2.96 | 2.34 | 3.73 | <0.001 | |
| (60-80) vs (80-100) | 1.69 | 1.40 | 2.05 | <0.001 | |
| Gender (F vs M) | 0.89 | 0.76 | 1.04 | 0.150 | |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).